DICE Therapeutics Announces Completion of Enrollment in Phase 1 Clinical Trial of Lead Oral IL-17 Antagonist, DC-806, for the Treatment of Psoriasis
Topline proof-of-concept data in healthy volunteers and psoriasis patients expected in 2H 2022
Excerpt from the Press Release:
SOUTH SAN FRANCISCO, Calif., July 21, 2022 (GLOBE NEWSWIRE) — DICE Therapeutics, Inc. (Nasdaq: DICE), a biopharmaceutical company leveraging its proprietary technology platform to build a pipeline of novel oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas, today announced the completion of enrollment in the Company’s Phase 1 clinical trial of DC-806 in healthy volunteers and psoriasis patients. DC-806 is an orally-available, small molecule antagonist of the pro-inflammatory cytokine, interleukin-17 (IL-17), which is a validated drug target for the treatment of a variety of autoimmune and inflammatory diseases, including psoriasis.
The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to generate safety and pharmacokinetic data and provide early clinical proof-of-concept in psoriasis patients. The trial is being conducted in three overlapping parts: Phase 1a (single ascending dose) and Phase 1b (multiple ascending dose) in healthy volunteers, and a Phase 1c (proof-of-concept) in psoriasis patients.
“Completion of enrollment in the Phase 1 study of DC-806 is an important step towards our objective of providing transformative oral medicines to patients suffering from psoriasis and other chronic autoimmune and inflammatory disorders,” said Kevin Judice, Ph.D., CEO of DICE Therapeutics. “IL-17 is a validated and powerful driver of psoriasis and we believe this ongoing Phase 1 study will provide us with early safety and proof-of-concept data, as well as dose selection guidance for future studies. We look forward to topline data across all three parts of the Phase 1 expected in the second half of 2022.”
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?